Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, placebo-controlled, patient and investigator blinded, Proof of Concept study investigating the safety, tolerability and preliminary efficacy of multiple intra-articular LNA043 injections in regenerating the articular cartilage of the knee in patients with articular cartilage lesions.

Trial Profile

A randomized, placebo-controlled, patient and investigator blinded, Proof of Concept study investigating the safety, tolerability and preliminary efficacy of multiple intra-articular LNA043 injections in regenerating the articular cartilage of the knee in patients with articular cartilage lesions.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs LNA 043 (Primary)
  • Indications Cartilage disorders
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Novartis Pharma A.G.
  • Most Recent Events

    • 21 Nov 2018 Planned End Date changed from 11 Dec 2018 to 16 Sep 2019.
    • 21 Nov 2018 Planned primary completion date changed from 11 Dec 2018 to 16 Sep 2019.
    • 12 Mar 2018 Planned End Date changed from 28 Sep 2018 to 11 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top